Fate Therapeutics, Inc. - Common Stock (FATE)

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.

FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.

FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.

Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%.

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on Tuesday.